Logo image of B8FK.DE

BIOFRONTERA AG (B8FK.DE) Stock Fundamental Analysis

FRA:B8FK - DE000A4BGGM7 - Common Stock

2.55 EUR
0 (0%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

1

Taking everything into account, B8FK scores 1 out of 10 in our fundamental rating. B8FK was compared to 50 industry peers in the Pharmaceuticals industry. B8FK may be in some trouble as it scores bad on both profitability and health. B8FK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

B8FK had negative earnings in the past year.
B8FK had a negative operating cash flow in the past year.
In the past 5 years B8FK reported 4 times negative net income.
B8FK had negative operating cash flow in 4 of the past 5 years.
B8FK.DE Yearly Net Income VS EBIT VS OCF VS FCFB8FK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

The Return On Assets of B8FK (-14.67%) is worse than 76.00% of its industry peers.
B8FK's Return On Equity of -23.07% is on the low side compared to the rest of the industry. B8FK is outperformed by 78.00% of its industry peers.
Industry RankSector Rank
ROA -14.67%
ROE -23.07%
ROIC N/A
ROA(3y)-50.28%
ROA(5y)N/A
ROE(3y)-80.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
B8FK.DE Yearly ROA, ROE, ROICB8FK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

With a decent Gross Margin value of 75.41%, B8FK is doing good in the industry, outperforming 74.00% of the companies in the same industry.
In the last couple of years the Gross Margin of B8FK has declined.
B8FK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
B8FK.DE Yearly Profit, Operating, Gross MarginsB8FK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 100 -100

More info and screens

3

2. Health

2.1 Basic Checks

B8FK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for B8FK has been increased compared to 1 year ago.
B8FK has a better debt/assets ratio than last year.
B8FK.DE Yearly Shares OutstandingB8FK.DE Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M
B8FK.DE Yearly Total Debt VS Total AssetsB8FK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -4.67, we must say that B8FK is in the distress zone and has some risk of bankruptcy.
B8FK has a worse Altman-Z score (-4.67) than 80.00% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that B8FK is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, B8FK belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -4.67
ROIC/WACCN/A
WACC7.06%
B8FK.DE Yearly LT Debt VS Equity VS FCFB8FK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

B8FK has a Current Ratio of 1.55. This is a normal value and indicates that B8FK is financially healthy and should not expect problems in meeting its short term obligations.
B8FK's Current ratio of 1.55 is fine compared to the rest of the industry. B8FK outperforms 66.00% of its industry peers.
A Quick Ratio of 1.02 indicates that B8FK should not have too much problems paying its short term obligations.
B8FK has a better Quick ratio (1.02) than 62.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.02
B8FK.DE Yearly Current Assets VS Current LiabilitesB8FK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

B8FK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -915.32%.
B8FK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -32.82%.
B8FK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -9.04% yearly.
EPS 1Y (TTM)-915.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%122.55%
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%55.35%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
B8FK.DE Yearly Revenue VS EstimatesB8FK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
B8FK.DE Yearly EPS VS EstimatesB8FK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

B8FK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
B8FK is valuated rather expensively with a Price/Forward Earnings ratio of 23.28.
Based on the Price/Forward Earnings ratio, B8FK is valued a bit more expensive than the industry average as 60.00% of the companies are valued more cheaply.
B8FK's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.69.
Industry RankSector Rank
PE N/A
Fwd PE 23.28
B8FK.DE Price Earnings VS Forward Price EarningsB8FK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
B8FK.DE Per share dataB8FK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

B8FK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for B8FK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA AG

FRA:B8FK (9/5/2025, 7:00:00 PM)

2.55

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-31 2025-05-31
Earnings (Next)09-30 2025-09-30
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.23%
Ins Owner ChangeN/A
Market Cap15.50M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 23.28
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.87
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)0.11
Fwd EY4.3%
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS3.56
BVpS3.1
TBVpS2.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.67%
ROE -23.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.41%
FCFM N/A
ROA(3y)-50.28%
ROA(5y)N/A
ROE(3y)-80.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
F-Score2
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.03%
Cap/Sales 0.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.02
Altman-Z -4.67
F-Score2
WACC7.06%
ROIC/WACCN/A
Cap/Depr(3y)90.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.54%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-915.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%122.55%
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%55.35%
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-208.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.28%
OCF growth 3YN/A
OCF growth 5YN/A